Specificity of vascular endothelial growth factor treatment for radiation necrosis

Carlos J. Perez-Torres; Liya Yuan; Robert E. Schmidt; Keith M. Rich; Robert E. Drzymala; Dennis E. Hallahan; Joseph J.H. Ackerman; Joel R. Garbow

doi:10.1016/j.radonc.2015.09.004

Specificity of vascular endothelial growth factor treatment for radiation necrosis

Carlos J. Perez-Torres, Liya Yuan, Robert E. Schmidt, Keith M. Rich, Robert E. Drzymala, Dennis E. Hallahan, Joseph J.H. Ackerman, Joel R. Garbow

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.

Original language	English
Pages (from-to)	382-385
Number of pages	4
Journal	Radiotherapy and Oncology
Volume	117
Issue number	2
DOIs	https://doi.org/10.1016/j.radonc.2015.09.004
State	Published - Nov 1 2015

Keywords

Magnetic resonance imaging
Radiation necrosis
Vascular endothelial growth factor

Access to Document

10.1016/j.radonc.2015.09.004

Cite this

@article{62022b48b3f24cd9b816e40944c22c36,

title = "Specificity of vascular endothelial growth factor treatment for radiation necrosis",

abstract = "Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.",

keywords = "Magnetic resonance imaging, Radiation necrosis, Vascular endothelial growth factor",

author = "Perez-Torres, {Carlos J.} and Liya Yuan and Schmidt, {Robert E.} and Rich, {Keith M.} and Drzymala, {Robert E.} and Hallahan, {Dennis E.} and Ackerman, {Joseph J.H.} and Garbow, {Joel R.}",

note = "Funding Information: This project was supported by NIH grant R01 CA155365 (J.R.G.), and funding from the Alvin J. Siteman Comprehensive Cancer Center ( P30 CA091842 ), the Barnes-Jewish Hospital Foundation Cancer Frontier Fund, Mallinckrodt Institute of Radiology , and Elekta Instruments AB (Stockholm, Sweden). We gratefully acknowledge Genentech (South San Francisco, CA) for donation of the antibodies B20-4.1.1 and GP120:9239. We also wish to thank Messrs. John Engelbach and Jeremy Cates for their help with the irradiation of the animals. Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.radonc.2015.09.004",

language = "English",

volume = "117",

pages = "382--385",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

number = "2",

}

TY - JOUR

T1 - Specificity of vascular endothelial growth factor treatment for radiation necrosis

AU - Perez-Torres, Carlos J.

AU - Yuan, Liya

AU - Schmidt, Robert E.

AU - Rich, Keith M.

AU - Drzymala, Robert E.

AU - Hallahan, Dennis E.

AU - Ackerman, Joseph J.H.

AU - Garbow, Joel R.

N1 - Funding Information: This project was supported by NIH grant R01 CA155365 (J.R.G.), and funding from the Alvin J. Siteman Comprehensive Cancer Center ( P30 CA091842 ), the Barnes-Jewish Hospital Foundation Cancer Frontier Fund, Mallinckrodt Institute of Radiology , and Elekta Instruments AB (Stockholm, Sweden). We gratefully acknowledge Genentech (South San Francisco, CA) for donation of the antibodies B20-4.1.1 and GP120:9239. We also wish to thank Messrs. John Engelbach and Jeremy Cates for their help with the irradiation of the animals. Publisher Copyright: © 2015 Elsevier Ireland Ltd.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.

AB - Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.

KW - Magnetic resonance imaging

KW - Radiation necrosis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84952636728&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.09.004

DO - 10.1016/j.radonc.2015.09.004

M3 - Article

C2 - 26376163

AN - SCOPUS:84952636728

SN - 0167-8140

VL - 117

SP - 382

EP - 385

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 2

ER -

Specificity of vascular endothelial growth factor treatment for radiation necrosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this